Stichting Amsterdam UMC

Amsterdam University Medical Center (AUMC) is a leading medical center that combines complex high-quality patient care, innovative scientific research, and education of the next generation health care professionals. We believe that health care practice, research and education belong together, with each shaping and informing the other.

With over 16,000 people, the two locations of Amsterdam UMC work together to provide good and accessible care. Amsterdam UMC is focused on a future where diseases can be prevented and where patients receive the best treatments. The emphasis is on the complex treatment of rare disorders.

At Amsterdam UMC we train thousands of young people to become doctors, specialists or nurses. Amsterdam UMC has eight research institutes. The researchers affiliated with these are internationally among the top in medical scientific research. Through the cooperation of Amsterdam UMC with other hospitals in the region of Noord-Holland and Flevoland, the patient receives the highest quality of care in the right place. At Amsterdam UMC we offer excellent academic patient care, state-of-the-art scientific research and top-level education and training.

Amsterdam UMC has arisen from the (administrative) merger of Amsterdam’s two academic hospitals, the Academic Medical Center (AMC) and the VU University Medical Center (VUmc) in 2018. Amsterdam UMC represents the medical faculties of the two universities associated: the University of Amsterdam and the Vrije Universiteit Amsterdam.

Role within INTERCEPT

Clinical and translational research is the ‘core business’ of the IBD group at Amsterdam University Medical Center. Given the many interest areas related to IBD, researchers are divided into teams each with a specific focus while fostering close interaction and frequent meetings between the teams to enhance each other’s insights and to stimulate scientific exchange. AUMC also has strong research ties with the departments of imaging, immunology, clinical psychology, pharmacology and paediatrics. Fundamental and translational research of (gastro-) intestinal diseases is concentrated at the Tytgat Institute for Liver and Intestinal Research.

Within the INTERCEPT project, Prof Dr Geert D’Haens has the role as the overall INTERCEPT Project Coordinator. In addition to role as project coordinator, AUMC is responsible for the overall financial and legal management by AMR which is affiliated with the AUMC (WP 9) and is part of the strategic planning and management of the project and monitoring within the communication committee (WP 10)

Alongside the role of project coordinator, Prof Dr Geert D’Haens will lead the trial design and execution of the HALT-CD trial (WP 4). AUMC will provide the biomarker dataset from the LOVE-CD Reprevio study in order to analyse biomarker response to therapy, as well as coordinate the submission of the PREDICT-CD study protocol and lead on the enrolment of 1500 first-degree relatives of people living with Crohn’s disease within UMCU and UMG for the study (WP 3). In addition, AUMC will analyse biomarker performance, linking digital health to biomarkers and treatment pathways, structuring knowledge around pre-diagnostic biomarkers (WP 5).